Hair Relaxer Cancer Lawsuit: What’s Been Proven So Far

Last updated: July 2026

The hair relaxer cancer lawsuit is active but far from over. Nearly 12,000 cases are consolidated in federal court in Chicago. Peer-reviewed studies link frequent chemical relaxer use to roughly double the risk of uterine cancer. No trial has taken place and no settlement exists yet. The first bellwether trials are expected in 2027.

Thousands of women, most of them Black women who used chemical straighteners for years, say these products caused their cancer. This guide breaks down what the science shows, what judges have ruled, and what remains unproven as of July 2026.

What Has Been Proven in the Hair Relaxer Cancer Lawsuit?

“Proven” means two different things here. In science, proof comes from studies. In court, proof comes from verdicts. The two are at very different stages.

On the science side, large studies have found a consistent association between frequent relaxer use and uterine cancer. That evidence was strong enough for a federal judge to let the core claims move forward.

On the legal side, nothing has been decided. No jury has heard a case. No company has admitted fault, and every defendant denies that its products cause cancer. Plaintiffs have cleared the early hurdles, but they have not yet won anything.

What Does the Science Show?

The litigation began with one study. In October 2022, researchers with the National Institutes of Health published findings from the Sister Study, which followed 33,947 US women for about 11 years. Women who used chemical straighteners more than four times a year had about 2.5 times the uterine cancer risk of women who never used them. In absolute terms, estimated risk by age 70 rose from 1.64 percent to 4.05 percent.

More research followed. Here is how the key studies compare:

Researchers point to specific ingredients as the suspected cause. These include phthalates such as DEHP, parabens, and formaldehyde or formaldehyde-releasing preservatives. Several are endocrine disruptors, meaning they can interfere with the body’s hormones. Uterine and ovarian cancers are both hormone-sensitive, which is why these findings drew so much attention.

One caution: association is not the same as causation. Defense experts argue the studies cannot rule out other explanations. That fight over causation is the central battle in the courtroom right now.

What Has Happened in Court So Far?

The court record has moved quickly for a mass tort. Here are the milestones.

1. October 2022: The Sister Study is published. The first lawsuit is filed against L’Oréal and other manufacturers within days.
2. February 2023: The Judicial Panel on Multidistrict Litigation consolidates the federal cases into MDL 3060 before Judge Mary Rowland in the Northern District of Illinois.
3. November 2023: Judge Rowland largely denies the companies’ motions to dismiss. A few claims are trimmed, but the core negligence and failure-to-warn claims survive. This was the plaintiffs’ first major win.
4. 2024-2025: The docket grows from a few hundred cases to more than 11,000. Both sides exchange documents and depose company witnesses.
5. December 2025 to January 2026: The parties exchange expert reports on general causation, the question of whether relaxers can cause these cancers at all. The court holds a Science Day in January 2026, where experts present the research directly to the judge.
6. April 2026: Judge Rowland takes direct control of selecting bellwether cases, the early test trials, and expands the pool of cases in trial workup. [VERIFY exact bellwether case counts]
7. Late 2026: Daubert motions, which decide whether each side’s experts may testify, move toward rulings. Case-specific expert and summary judgment motions are due in November 2026. [VERIFY]

As of July 1, 2026, 11,877 cases were pending in the MDL, making it one of the largest active mass torts in the country. Additional cases are pending in state courts.

Which Companies and Products Are Named?

The lawsuits target the makers of the most widely sold chemical relaxers. Named defendants include:

• L’Oréal USA and SoftSheen-Carson: Dark & Lovely and Optimum relaxers
• Strength of Nature (Godrej): Just For Me, Motions, African Pride, and TCB Naturals
• Namaste Laboratories (Dabur): ORS Olive Oil relaxers
• Avlon Industries: Affirm relaxers
• Revlon: claims are complicated by the company’s 2022 bankruptcy, though insurance may cover some liability

Product identification matters. Your claim can only proceed against the companies whose relaxers you actually used.

Who Qualifies to File a Claim?

Law firms screening hair relaxer cases generally look for three things:

• Regular use. Most firms want to see chemical relaxer use several times a year, often for years at a stretch. That matches the exposure levels tied to higher risk in the studies.
• A qualifying diagnosis. Uterine cancer, endometrial cancer, and ovarian cancer are the core diagnoses accepted in the MDL.
• Timing. The diagnosis generally must come after a period of relaxer use, and the claim must be filed within your state’s legal deadline.

Women who had hysterectomies for fibroids alone, without a cancer diagnosis, have generally not been accepted into the federal litigation, because the cancer research is the backbone of the case.

Has Anyone Received a Settlement Yet?

No. As of July 2026 there have been no verdicts and no global settlement in the hair relaxer cancer lawsuit. Any website or advertisement promising a specific payout is guessing.

That said, the machinery for settlement exists. The court has appointed a special master to facilitate talks between the parties. In most mass torts, serious negotiations begin after the expert rulings and the first bellwether verdicts, because those results show both sides what juries are likely to do.

Some plaintiffs’ firms have published payout projections for strong uterine cancer cases. Treat those figures as marketing estimates, not promises. Real values will depend on the Daubert rulings, trial outcomes, and each woman’s diagnosis, age, treatment history, and product use.

What Happens Next?

The rest of 2026 is about experts. If Judge Rowland allows the plaintiffs’ causation experts to testify, the litigation moves toward trials with real settlement pressure on the companies. If she excludes them, the cases could collapse. This is the single most important upcoming ruling.

The first bellwether trials are expected in 2027. Meanwhile, the FDA’s proposed rule to ban formaldehyde in hair straightening products, first announced in 2023, had still not been finalized as of mid-2026. [VERIFY current FDA rule status]

Hair Relaxer Cancer Lawsuit FAQs

Has the hair relaxer lawsuit been settled?

No. As of July 2026 there is no settlement and no jury verdict. Nearly 12,000 cases are pending in the federal MDL in Chicago, with more in state courts. A special master is helping both sides talk, but most observers expect serious settlement negotiations only after expert rulings and the first trials in 2027.

Which cancers qualify for a hair relaxer claim?

Most firms accept uterine cancer, endometrial cancer, and ovarian cancer, because those diagnoses have the strongest research support. Breast cancer and fibroid-only cases are generally declined in the federal litigation since the scientific link is weaker. Screening criteria vary by firm, so a decline from one firm does not always mean a decline from all.

How long do I have to file?

Deadlines come from state statutes of limitations, which typically run one to six years from diagnosis, with two or three years being common. Some states extend the clock under a discovery rule if you only recently learned of the possible link. Because the rules vary widely, speak with a lawyer promptly after diagnosis.

Do I need receipts to prove which relaxer I used?

No. Almost no one keeps decades of receipts. Firms typically rely on sworn statements about the brands you used, photos, old product containers, salon records, and statements from family members or stylists. Product identification still matters, because you can only bring claims against the makers of relaxers you actually used.

When will the first hair relaxer trial happen?

The first bellwether trials in MDL 3060 are expected in 2027, after the court rules on expert testimony in late 2026. No firm trial date had been announced as of July 2026. Bellwether verdicts are not binding on other cases, but they heavily influence settlement values for everyone else.

The Bottom Line

The hair relaxer cancer lawsuit has cleared every early hurdle, but the hardest tests are still ahead. The science showing an association is real and peer reviewed. Court proof, in the form of expert rulings and jury verdicts, has not happened yet. For women with a qualifying diagnosis, the practical steps are simple: document your product use, gather your medical records, and talk to a lawyer before your state’s deadline passes.

This article is general information, not legal or medical advice. Litigation facts change quickly. For guidance on your specific situation, consult a licensed attorney in your state.